Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KarXT + lecanemab
- Development stage
- Unknown
- Lead developer
- Neurology Office of South Florida
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
KarXT + lecanemab is a combination therapy regimen being investigated for the treatment of Alzheimer's disease. KarXT is a co-formulation of xanomeline, a dual M1/M4-preferring muscarinic acetylcholine receptor agonist, and trospium chloride, a peripherally restricted muscarinic antagonist designed to mitigate peripheral cholinergic side effects. Lecanemab is a humanized IgG1 monoclonal antibody that selectively binds to soluble amyloid-beta (Aβ) protofibrils, promoting their clearance from the brain. This combination approach aims to provide symptomatic relief of cognitive and neuropsychiatric symptoms via muscarinic modulation while simultaneously addressing the underlying amyloid pathology of the disease. The Neurology Office of South Florida is conducting a Phase II study to evaluate the safety and tolerability of adding KarXT to patients already receiving lecanemab infusions.
- Brand names
- Leqembi
- Other names
- Xanomeline + Trospium + LecanemabX/T + X-EC + LecanemabXanomeline/Trospium + Lecanemab
02
Targets
Amyloid fibrilsAmyloid-β protofibrilsM1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)
Beyond the preview
Go deeper on KarXT + lecanemab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KarXT + lecanemab.